Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
Globe Newswire•18/11/2026•07:00 ET
0
Key Highlights
- ➤ASCEND Phase 2b doses first patient, evaluating VIS-101 in wet AMD
- ➤Approximately 244 patients receive 6 mg or 9 mg VIS-101 versus aflibercept
- ➤Phase 2a: approximately 50% of 6 mg patients remained retreatment-free six months
- ➤ASCEND tests treatment intervals up to seven months after monthly loading doses
- ➤Global Phase 3 initiation planned as early as 2027
Expert Statements
Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara
“Dosing the first patient in the ASCEND study marks an important milestone for VIS-101 and brings us closer to determining whether the encouraging durability we saw in the Phase 2a trial can translate into meaningfully longer treatment intervals for patients with wet AMD.”
Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara
“While available therapies have transformed the treatment of wet AMD, the need for frequent injections remains a significant burden for patients, caregivers and physicians.”
Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara
“Our goal with VIS-101 is to maintain strong disease control while enabling patients to go substantially longer between injections following loading.”
Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara
“The ASCEND study is designed to test that potential directly against an established standard of care.”
Cadmus Rich, M.D., M.B.A, Chief Medical Officer of Visara
“VIS-101 was purpose-designed with durability in mind, combining tetravalent inhibition of VEGF-A and ANG-2 with favorable pharmacokinetic properties intended to extend its activity in the eye.”
Cadmus Rich, M.D., M.B.A, Chief Medical Officer of Visara
“The encouraging durability observed in the Phase 2a study provides a strong scientific foundation for the ASCEND study, which is designed to further characterize VIS-101’s properties in a larger, head-to-head trial.”
Head-to-head trial designed to evaluate VIS-101’s potential for sustained disease control with extended treatment intervals
Phase 2a results showed approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose
Get started
Create a free account to read the full story.
